Depression Evaluation Service - New York State Psychiatric Institute
New York, 10032, United States
NCT Number: NCT00296712
Relatively drug naive patients will receive two antidepressant medications as initial treatment.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
New York, 10032, United States
While antidepressant medications are often effective in relieving depressive symptoms, at least 60% of patients do not remit with the first agent tried. This pilot study will assess whether giving two standard medications simultaneously (i.e., Escitalopram and Bupropion) is both tolerated and improves response while decreasing drop outs. This is a replication of a previous study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
same dosing as for monotherapy arms
Other names: escitalopram = Lexapro, bupropion = Wellbutrin
Time frame: 10 weeks
Time frame: 10 weeks
Time frame: 10 weeks
Time frame: 10 weeks
Time frame: 10 weeks
New York State Psychiatric Institute
Other
Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04235712
Depressive Disorder, Depressive Disorder, Major
Springfield, Massachusetts, United States
View Trial DetailsNCT04235725
Depressive Disorder, Depressive Disorder, Major
Washington D.C., District of Columbia, United States
View Trial DetailsNCT00296725
Depressive Disorder, Depressive Disorder Not Otherwise Specified
New York, United States
View Trial DetailsNCT00565110
Depressive Disorder, Depressive Disorder, Major
Los Angeles, California, United States
View Trial Details